The Federal Trade Commission’s Feb.4 consent order with Express Scripts represents the most consequential structural overhaul of the pharmacy benefit manager industry to date. Policymakers and ...

A Chicago plumbers’ union is accusing Express Scripts Inc. of giving certain drugmakers preferential patient access in exchange for billions of dollars in rebates it withheld from the union health ...

On February 4, 2026, Express Scripts agreed to a settlement with the Federal Trade Commission (FTC) in the agency’s administrative case against the nation’s three largest pharmacy benefit managers ...

The Federal Trade Commission has announced what it called a "landmark settlement" with Express Scripts over insulin pricing. The settlement resolves a lawsuit alleging that Express Scripts' conduct ...

The Federal Trade Commission has agreed to what it called a “landmark” settlement with Express Scripts, allowing the company to bow out of the agency’s lawsuit against major pharmacy benefit managers ...

The FTC first sued Express Scripts, CVS Caremark, and Optum in 2024, claiming anticompetitive and unfair rebating practices surrounding insulin. “Caremark, [Express Scripts], and Optum—as medication ...

The Federal Trade Commission has reached a landmark settlement with Express Scripts, one of the nation’s largest pharmacy benefit managers, requiring sweeping changes aimed at lowering insulin costs ...

The Federal Trade Commission said it has reached a settlement with Express Scripts, resolving an earlier lawsuit that alleged the pharmacy benefit manager artificially inflated insulin drug prices.

The Trump administration announced that the company, a pharmacy benefit manager, had agreed to make significant changes to its practices. By Rebecca Robbins and Reed Abelson The reporters have ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...

Broader formulary inclusion of lower-priced drugs and standardized $25/month insulin caps are designed to mitigate rebate-driven selection and reduce patient cost exposure to pre-rebate prices. Lowest ...